Hepatitis B virus (HBV) is an etiological agent of hepatitis B infection. Hepatitis B is a life-threatening disease that affects the liver. The clinical outcomes of the disease are varied from asymptomatic disease to serious complication such as cirrhosis and hepatocellular carcinoma (HCC). Despite availability of the vaccine and appropriate treatment, hepatitis B infection still remains a majo...

introduction: zinc deficiency causes abnormalities in immune response. in chronic hemodialysis (hd) and continuous ambulatory peritoneal dialysis (capd) patients, impaired immune responses to vaccination have been reported. therefore, we performed a study to determine the correlation between serum zinc levels and immune response to hepatitis b vaccination in patients on dialysis. methods: a cro...

the immune response to hepatitis b surface antigen (hbsag) is influenced by several factors, of which hla antigens and balanced secretion of th1/th2 cytokines play important roles. the aim of this study was to evaluate the influence of hla antigens on cytokine secretion by hbsag-stimulated peripheral blood mononuclear cells (pbmc) from healthy neonates vaccinated with recombinant hbsag. pbmcs w...

background: several adjuvants have been evaluated for vaccine formulations but alu-minum salts will continue to be used for many years due to their safety, low cost and adjuvanticity with different antigens. two commonly used aluminum adjuvants, alumi-num hydroxide and aluminum phosphate have different adjuvanticity properties. com-mercial recombinant protein hepatitis b vaccines containing alu...

NL Biotechnologies is a biotech R&D company that specializes in viral Hepatitis B, C, and E vaccine development. The proprietary recombinant Hepatitis B vaccine technology has been commercialized in 2002 by Instituto Butantan (Brazil) and in 2004 by Probiomed S.A. de C.V. (Mexico). The overall sales exceed 200 million doses. Since 2001, NL Biotechnologies in collaboration with CDC (US, Atlanta)...

CONTEXT The association between infant age at initiation of hepatitis B vaccination and completion of the 3-dose hepatitis B vaccination series is unclear. OBJECTIVE To assess the association between administration of the first dose of hepatitis B vaccine within 7 days of birth and completion of the hepatitis B vaccine series and the 4:3:1:3 vaccine series (4 doses of diphtheria-tetanus-pertu...

OBJECTIVE To determine the cost-effectiveness of substituting hepatitis A-B vaccine for hepatitis B vaccine when healthcare and public safety workers in the western United States are immunized to protect against occupational exposures to hepatitis B. PARTICIPANTS A cohort of 100,000 hypothetical healthcare and public safety workers from 11 western states with hepatitis A rates twice the natio...

Acute hepatitis A superimposed on chronic liver disease (CLD) has been associated with severe or fulminant hepatitis. An open, multicenter study was performed to compare the safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in healthy subjects. A secondary objective was to compare the safety of the hepatitis A vaccine with that of a commercial hepati...

The human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted...